A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors

References

• FogariRZoppiANew class of agents for treatment of hypertension: focus on direct renin inhibitionVasc Health Risk Manag2010686988220957132
   PubMedGoogle Scholar
• SeverPSGradmanAHAziziMManaging cardiovascular and renal risk: the potential of direct renin inhibitionJ Renin Angiotensin Aldosterone Syst2009102657619502253
   PubMed Web of Science ®Google Scholar
• VolpeMSavoiaCDe PaolisPOstrowskaBTarasiDRubattuSThe renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal diseaseJ Am Soc Nephrol200213Suppl 3S173S17812466309
   PubMedGoogle Scholar
• GullapalliNBlochMJBasileJRenin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trendsTher Adv Cardiovasc Dis20104635937320965951
   PubMedGoogle Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• KarlbergBECough and inhibition of the renin-angiotensin systemJ Hypertens199311Suppl 3S49S52
   PubMedGoogle Scholar
• DicpinigaitisPVAngiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelinesChest20061291 Suppl169S173S16428706
   PubMed Web of Science ®Google Scholar
• SicaDABlackHRAngioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapyCongest Heart Fail20028633434134512461324
   PubMedGoogle Scholar
• GrossmanEMesserliFHGoldbourtUAntihypertensive therapy and the risk of malignanciesEur Heart J200122151343135211465967
   PubMed Web of Science ®Google Scholar
• FriisSSorensenHTMellemkjaerLAngiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in DenmarkCancer20019292462247011745304
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFRepaciSMazzottaGGentileGReboldiGComparative assessment of angiotensin receptor blockers in different clinical settingsVasc Health Risk Manag2009593994819997575
   PubMedGoogle Scholar
• StraussMHHallASAngiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradoxCirculation2006114883885416923768
   PubMed Web of Science ®Google Scholar
• SipahiIDebanneSMRowlandDYSimonDIFangJCAngiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trialsLancet Oncol201011762763620542468
   PubMed Web of Science ®Google Scholar
• VermaSStraussMAngiotensin receptor blockers and myocardial infarctionBMJ200432974771248124915564232
   PubMed Web of Science ®Google Scholar
• SanoskiCAAliskiren: an oral direct renin inhibitor for the treatment of hypertensionPharmacotherapy200929219321219170589
   PubMed Web of Science ®Google Scholar
• WhiteWBBresalierRKaplanAPSafety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertensionJ Clin Hypertens (Greenwich)2010121076577521029339
   PubMed Web of Science ®Google Scholar
• BezenconOBurDWellerTDesign and preparation of potent, nonpeptidic, bioavailable renin inhibitorsJ Med Chem200952123689370219358611
   PubMed Web of Science ®Google Scholar
• TiceCMXuZYuanJDesign and optimization of renin inhibitors: Orally bioavailable alkyl aminesBioorg Med Chem Lett200919133541354519457666
   PubMed Web of Science ®Google Scholar
• FyhrquistFSaijonmaaORenin-angiotensin system revisitedJ Intern Med2008264322423618793332
   PubMed Web of Science ®Google Scholar
• SiragyHMComparing angiotensin II receptor blockers on benefits beyond blood pressureAdv Ther201027525728420524096
   PubMed Web of Science ®Google Scholar
• ZhengZShiHJiaJLiDLinSA systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertensionJ Renin Angiotensin Aldosterone Syst2010118 [Epub ahead of print].
   Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBLewisEJHollenbergNKAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• McMurrayJJPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail20081172419808266
   PubMed Web of Science ®Google Scholar
• SolomonSDAppelbaumEManningWJEffect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both, on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation2009119453053719153265
   PubMed Web of Science ®Google Scholar
• SolomonSDHeeSSShahAEffect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunctionEur Heart J2011 [Epub ahead of print].
   Google Scholar
• MazzolaiLBurnierMComparative safety and tolerability of angiotensin II receptor antagonistsDrug Saf1999211233310433351
   PubMed Web of Science ®Google Scholar
• Cozaar^® (losartan potassium tablets) [prescribing information]2006Merck and Co., IncWhitehouse Station, NJ
   Google Scholar
• Diovan^® (valsartan) Tablets [prescribing information]2008Novartis Pharmaceuticals CorporationEast Hanover, NJ
   Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• McMurrayJAngiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurateBMJ20053307502126915920134
   PubMedGoogle Scholar
• OpieLHAngiotensin receptor blockers and myocardial infarction: direct comparative studies are neededBMJ200533075021270127115920136
   PubMedGoogle Scholar
• LewisEJAngiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetesBMJ200533075021269127015920133
   PubMedGoogle Scholar
• TsuyukiRTMcDonaldMAAngiotensin receptor blockers do not increase risk of myocardial infarctionCirculation2006114885586016923769
   PubMed Web of Science ®Google Scholar
• YousefZRLeyvaFGibbsCAngiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credibleBMJ200533075021270127115920135
   PubMedGoogle Scholar
• VerdecchiaPAngeliFGattobigioRReboldiGPDo angiotensin II receptor blockers increase the risk of myocardial infarction?Eur Heart J200526222381238616081468
   PubMed Web of Science ®Google Scholar
• McDonaldMASimpsonSHEzekowitzJAGyenesGTsuyukiRTAngiotensin receptor blockers and risk of myocardial infarction: systematic reviewBMJ2005331752187316183653
   PubMedGoogle Scholar
• VolpeMManciaGTrimarcoBAngiotensin II receptor blockers and myocardial infarction: deeds and misdeedsJ Hypertens200523122113211816269950
   PubMed Web of Science ®Google Scholar
• CheungBMCheungGTLauderIJLauCPKumanaCRMeta-analysis of large outcome trials of angiotensin receptor blockers in hypertensionJ Hum Hypertens2006201374316121197
   PubMed Web of Science ®Google Scholar
• MesserliFHBangaloreSRuschitzkaFAngiotensin receptor blockers: baseline therapy in hypertension?Eur Heart J200930202427243019723696
   PubMed Web of Science ®Google Scholar
• WalkerEHernandezAVKattanMWMeta-analysis: Its strengths and limitationsCleve Clin J Med200875643143918595551
   PubMed Web of Science ®Google Scholar
• SuzukiHKannoYEffects of candesartan on cardiovascular outcomes in Japanese hypertensive patientsHypertens Res200528430731416138560
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• McMurrayJJHolmanRRHaffnerSMEffect of valsartan on the incidence of diabetes and cardiovascular eventsN Engl J Med2010362161477149020228403
   PubMed Web of Science ®Google Scholar
• SawadaTYamadaHDahlöfBMatsubaraHEffects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART StudyEur Heart J200930202461246919723695
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlofBShimizuMValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• SchraderJLudersSKulschewskiAMorbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)Stroke20053661218122615879332
   PubMed Web of Science ®Google Scholar
• GoldsteinMRMascitelliLPezzettaFAngiotensin-receptor blockade, cancer, and concernsLancet Oncol201011981781820816375
   PubMedGoogle Scholar
• KanehiraTTaniTTakagiTNakanoYHowardEFTamuraMAngiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-b-dependent cell growth attenuationCancer Res200565177660766516140932
   PubMed Web of Science ®Google Scholar
• ClereNCorreIFaureSDef iciency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesisInt J Cancer2010127102279229120143398
   PubMed Web of Science ®Google Scholar
• MeredithPAMcInnesGTAngiotensin-receptor blockade, cancer, and concernsLancet Oncol201011981920816377
   PubMedGoogle Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• BangaloreSKumarSKjeldsenSEAntihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trialsLancet Oncol2011121658221123111
   PubMed Web of Science ®Google Scholar
• The ARB Trialists CollaborationEffects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individualsJ Hypertens201129462363521358417
   PubMed Web of Science ®Google Scholar
• HuangCCChanWLChenYCAngiotensin II receptor blockers and risk of cancer in patients with systemic hypertensionAm J Cardiol201110771028103321256465
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety CommunicationOngoing safety review of the angiotensin receptor blockers and cancer2010 Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation-forPatientsandProviders/ucm218845.htm. Accessed March 2011.
   Google Scholar
• Tekturna^® (aliskiren) Tablets, Oral [prescribing information]2010Novartis Pharmaceuticals CorporationEast Hanover, NJ
   Google Scholar
• Atacand^® (candesartan cilexetil) Tablets [prescribing information]2009AstraZeneca LPWilmington, DE
   Google Scholar
• Avapro^® (irbesartan) Tablets [prescribing information]2007Bristol Myers Squibb Sanofi-Synthelabo PartnershipNew York, NY
   Google Scholar
• Micardis^® (telmisartan) Tablets [prescribing information]2009Boehringer Ingelheim Pharmaceuticals, Inc.Ridgefield, CT
   Google Scholar
• Teveten^® (eprosartan mesylate) Tablets [prescribing information]2007Abbott LaboratoriesNorth Chicago, IL
   Google Scholar
• Benicar^® (olmesartan medoxomil) Tablets [prescribing information]2009Daiichi Sankyo, Inc.Parsippany, NJ
   Google Scholar
• SolomonSDWangDFinnPEffect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programCirculation2004110152180218315466644
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• McMurrayJSolomonSPieperKThe effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)J Am Coll Cardiol200647472673316487836
   PubMedGoogle Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• BerlTHunsickerLGLewisJBCardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyAnn Intern Med2003138754254912667024
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE IILancet200035592151582158710821361
   PubMed Web of Science ®Google Scholar